Kiniksa director receives 683 RSUs, converts to shares

Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported equity compensation activity involving restricted share units and ordinary shares.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported equity compensation activity involving restricted share units and ordinary shares. On February 1, 2026, he received a grant of 683 Restricted Share Units, each representing the right to receive one Class A Ordinary Share.

The RSUs vested immediately upon grant on February 1, 2026 and had no expiration date. On the same date, 683 RSUs were settled, resulting in the acquisition of 683 Class A Ordinary Shares at a price of $0. Following these transactions, Levy directly owned 19,157 Class A Ordinary Shares.

Insider Trade Summary

683 shares exercised/converted

Exercise 3 txns

Insider Levy Richard S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	683	$0.00	$0.00
Exercise	Restricted Share Units	683	$0.00	$0.00
Exercise	Class A Ordinary Share	683	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 0 contracts (Direct); Class A Ordinary Share — 19,157 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
2. F2. The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kiniksa (KNSA) director Richard S. Levy report?

Kiniksa director Richard S. Levy reported equity compensation activity involving restricted share units and ordinary shares. On February 1, 2026, he received 683 Restricted Share Units that vested immediately and were settled into 683 Class A Ordinary Shares at $0, increasing his directly held share balance.

How many Kiniksa (KNSA) Restricted Share Units were granted to Richard S. Levy?

Richard S. Levy was granted 683 Restricted Share Units of Kiniksa on February 1, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share, and these RSUs vested immediately upon grant according to the filing’s explanatory footnotes.

When did Richard S. Levy’s Kiniksa RSUs vest and how were they settled?

The Restricted Share Units granted to Richard S. Levy vested immediately on February 1, 2026. On that same date, 683 RSUs were settled by issuing 683 Class A Ordinary Shares at a price of $0, reflecting a standard equity compensation settlement structure.

How many Kiniksa Class A Ordinary Shares does Richard S. Levy own after this Form 4?

After the reported transactions, Richard S. Levy directly owned 19,157 Kiniksa Class A Ordinary Shares. This figure reflects his holdings following the conversion of 683 vested Restricted Share Units into an equal number of Class A Ordinary Shares at no cash cost per share.

Did the Kiniksa RSUs reported by Richard S. Levy have an expiration date?

The Restricted Share Units reported by Richard S. Levy did not have an expiration date. The filing states that the RSUs vested immediately upon grant on February 1, 2026, and therefore there was no expiration date associated with these particular equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Richard S

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	02/01/2026		M		683	A	(1)	19,157	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	02/01/2026		A		683		(2)	(2)	Class A Ordinary Shares	683	$0	683	D
Restricted Share Units	(1)	02/01/2026		M			683	(2)	(2)	Class A Ordinary Shares	683	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs.

	/s/ Douglas Barry, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.